相关实验视频

Updated: Feb 28, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

一种基于PLGA的阿巴特默输送系统,用于在绿眼镜过手术后调节副结膜纤维化

Wangdu Luo¹, Lingling Li², Yi Lin³

¹Department of Ophthalmology,, Chongqing Medical University, No.1 Shuanghu Branch Road, Huixing Street, Liangjiang New District, Chongqing, Chongqing, Chongqing, 400016, China.

Biomedical materials (Bristol, England)

|February 25, 2026

概括

这项研究开发了poly ((乳酸-co-甘油酸) -S58纳米颗粒,以减少青光眼手术后的痕. 新型纳米粒子改善了药物输送,减少了纤维化,并降低了老鼠模型中的眼睛压力.

科学领域:

生物材料科学生物材料科学
眼科医生眼科眼科
纳米技术纳米技术

背景情况:

副结膜纤维化是绿眼镜过手术后失败的主要原因.
目前的治疗方法通常涉及细胞毒性抗代谢物,具有显著的副作用.
准转化生长因子-β (TGF-β) 途径是一种有前途的抗纤维菌策略.

研究的目的:

为了开发聚乳-co-glycolic 酸) 纳米颗粒封装TβRII向性亚体S58 (PLGA-S58).
为了评估PLGA-S58在玻璃眼透手术后的体外和体内抗纤维素疗效.
评估PLGA-S58对bleb功能和眼内压力 (IOP) 降低的影响.

主要方法:

准备了PLGA-S58纳米粒子,并根据大小,形态和药物释放进行了表征.
在体外研究中,在TGF-β2诱导的纤维化模型中使用了人类结膜纤维细胞 (HConFs).
在体内研究中使用了一种大鼠绿眼镜过手术模型,并进行了S58或PLGA-S58.8的子结膜给药.

主要成果:

PLGA-S58纳米颗粒在7天内显示了S58体的持续释放.
在实验室中,PLGA-S58有效抑制了HConF的增殖,迁移和纤维化标记物的表达.
在体内,PLGA-S58减少了原沉积和肌纤维细胞积累,改善了bleb功能和IOP控制.

结论:

PLGA-S58纳米颗粒提供了持续的局部输送抗纤维细胞吸收体.
这种系统增强了抗纤维素疗效和眼镜瘤手术后的血栓功能.
PLGA-S58显示出作为更安全,非细胞毒性替代品的潜力,用于管理子结膜纤维化.

关键词:

第3章没有了亚胺体 S5858 的使用情况眼光障碍的过手术是眼光障碍的过手术聚乳-同-甘油酸) (PLGA) 的使用.副结合膜纤维化持续的本地交付 1 介绍

更多相关视频

Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

Optimized Minimally Invasive Transscleral Subretinal Injection Technique in Mouse

Published on: July 25, 2025

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

相关概念视频

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...